Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
04:01pm, Thursday, 04'th Sep 2025
BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperido
Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet
10:56am, Monday, 01'st Sep 2025
The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High?
10:56am, Thursday, 14'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positiv
Here's Why Momentum in Amneal (AMRX) Should Keep going
09:51am, Wednesday, 13'th Aug 2025
If you are looking for stocks that are well positioned to maintain their recent uptrend, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price St
Amneal (AMRX) Q2 EPS Jumps 56%
04:39pm, Tuesday, 05'th Aug 2025
Amneal (AMRX) Q2 EPS Jumps 56%
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript
02:56pm, Tuesday, 05'th Aug 2025
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Anastasios G. Konidaris - Executive VP & CFO Anthony DiMeo - Head of Investo
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Tuesday, 05'th Aug 2025
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
08:15am, Tuesday, 05'th Aug 2025
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
07:30am, Tuesday, 05'th Aug 2025
MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo
Amneal Reports Second Quarter 2025 Financial Results
06:00am, Tuesday, 05'th Aug 2025
‒ Q2 2025 Net Revenue of $725 million ; GAAP Net Income of $22 million ; Diluted Income per Share of $0.07 ‒ ‒ Adjusted EBITDA of $184 million ; Adjusted Diluted EPS of $0.25 ‒ ‒ Raising 202
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Tuesday, 29'th Jul 2025
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
11:05am, Tuesday, 29'th Jul 2025
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet
10:56am, Tuesday, 29'th Jul 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positiv
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
10:41am, Monday, 28'th Jul 2025
Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
07:39am, Monday, 21'st Jul 2025
BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking
